Mesenchymal stem cells for the treatment of cns diseases
US-2016375098-A1 · Dec 29, 2016 · US
Isolated cells and populations comprising same for the treatment of CNS diseases
US9879225B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9879225-B2 |
| Application number | US-201414173846-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 6, 2014 |
| Priority date | Jun 16, 2005 |
| Publication date | Jan 30, 2018 |
| Grant date | Jan 30, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating amyotrophic lateral sclerosis (ALS) or Parkinson's disease comprising administering to an individual in need thereof a therapeutically effective amount of non-genetically modified GDNF-secreting cells which are ex vivo differentiated from human mesenchymal stem cells, wherein said GDNF-secreting cells express glutamate transporter 1 (GLT1), wherein said GDNF-secreting cells express CD90 and wherein a secretion of said GDNF is at least 5 times greater than a basal secretion of said GDNF in a non-differentiated, non-genetically modified human mesenchymal stem cell, thereby treating ALS or Parkinson's. 2. The method of claim 1 , wherein said cells which secrete GDNF are autologous to said individual. 3. The method of claim 1 , wherein said cells which secrete GDNF are non-autologous to said individual.
Assignees
Inventors
Classifications
- A61K35/28Primary
Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title
Epidermal growth factor [EGF] · CPC title
for treating abnormal movements, e.g. chorea, dyskinesia · CPC title
Drugs for disorders of the nervous system · CPC title
- C12N5/0622Primary
Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9879225B2 cover?
- An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype.
- Who is the assignee on this patent?
- Ramot At Tel-Aviv Univ Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K35/28. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).